This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Institute of Bioengineering and Biomedicine | |
|---|---|
| Name | Institute of Bioengineering and Biomedicine |
| Established | 1990s |
| Type | Research institute |
| Location | Shanghai |
| Campus | University of Science and Technology |
Institute of Bioengineering and Biomedicine is a multidisciplinary research institute focused on translational bioengineering and biomedical science. It integrates cellular engineering, biomaterials, tissue engineering, and medical devices to advance healthcare innovations. The institute engages with universities, hospitals, and industry partners to translate laboratory discoveries into clinical and commercial applications.
Founded in the late 20th century amid expansions in biomedical research at Shanghai Jiao Tong University, the institute emerged during a period marked by increased funding from entities such as the National Natural Science Foundation of China and initiatives like the 863 Program. Early collaborations involved researchers from Tsinghua University, Peking University, and the Chinese Academy of Sciences; partnerships with hospitals including Renji Hospital and Ruijin Hospital enabled clinical translation. Over time the institute participated in national projects tied to the National Key R&D Program of China and international exchanges with institutions such as Massachusetts Institute of Technology, Imperial College London, and the Max Planck Society.
The institute's mission aligns with goals articulated by bodies like the World Health Organization, emphasizing translational research impacting Food and Drug Administration-regulated therapies and devices approved by agencies analogous to the European Medicines Agency. Research areas include stem cell engineering influenced by work from Shinya Yamanaka and James Thomson, biomaterials development reflecting principles from Robert Langer and John A. Rogers, and mechanobiology tracing to studies by David Discher and Donald Ingber. Projects target regenerative medicine, drug delivery inspired by nanoengineering advances from Chad Mirkin and Paul Alivisatos, and biosensing technologies in the tradition of George M. Whitesides.
Governance comprises an executive director supported by an academic advisory board with members drawn from institutions such as Fudan University, Zhejiang University, and Harvard University. Administrative units mirror models from the National Institutes of Health intramural programs, with departments for Cellular Engineering, Biomaterials Science, Bioinstrumentation, and Clinical Translation. The institute hosts principal investigators who hold joint appointments with affiliated hospitals like Shanghai Sixth People's Hospital and international chairs linked to centers at University of California, Berkeley and Karolinska Institutet.
Laboratory infrastructure includes cell culture suites compliant with standards from the International Organization for Standardization, cleanrooms for microfabrication akin to facilities at Stanford University and electron microscopy centers comparable to those at the European Molecular Biology Laboratory. Core facilities provide next-generation sequencing platforms used in collaboration with Broad Institute, mass spectrometry labs paralleling Max Planck Institute for Biochemistry resources, and bioreactor suites for tissue engineering inspired by designs at Wyss Institute for Biologically Inspired Engineering. Clinical-grade production follows practices from GMP-certified facilities and biobank operations similar to the UK Biobank.
The institute offers graduate programs jointly administered with universities such as ShanghaiTech University and East China Normal University, training students through curricula influenced by programs at Johns Hopkins University and Duke University. Postdoctoral fellowships attract scholars funded by agencies like the China Scholarship Council and Marie Skłodowska-Curie Actions, and professional development includes translational courses modeled after workshops at the Bill & Melinda Gates Foundation and executive training seen at the Stanford Graduate School of Business.
Strategic partnerships span academic, clinical, and industrial sectors, with memoranda of understanding echoing collaborations between Pfizer, Novartis, and research universities. Joint research centers with hospitals such as Huashan Hospital and industry alliances with companies like Siemens Healthineers and Medtronic support device development and clinical trials consistent with protocols from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. International consortia include links to networks like Horizon 2020 projects and bilateral programs with National Institutes of Health research centers.
The institute contributed to engineered tissue constructs advancing concepts popularized by Anthony Atala and delivered biomaterial platforms that referenced breakthroughs by Mauro Ferrari and Maria Grazia Spillantini. Achievements include peer-reviewed publications in journals such as Nature, Science, Cell, Nature Biotechnology, and The Lancet, and patents filed in cooperation with entities like China National Intellectual Property Administration and World Intellectual Property Organization. The institute has hosted conferences with keynote speakers from Royal Society and served as a node in networks related to the Human Cell Atlas and International Society for Stem Cell Research.
Category:Research institutes Category:Biotechnology organizations